Publications

Select publications

Manuscripts

  1. Younossi Z, Brown A, Buti M, et al. Impact of eradicating hepatitis C virus on the work productivity of chronic hepatitis C (CH-C) patients: an economic model from five European countries. Journal of viral hepatitis. Mar 2016;23(3):217-226.
  2. Younossi ZM, Park H, Saab S, Ahmed A, Dieterich D, Gordon SC. Cost-effectiveness of all-oral ledipasvir/sofosbuvir regimens in patients with chronic hepatitis C virus genotype 1 infection. Alimentary pharmacology & therapeutics. Mar 2015;41(6):544-563.
  3. Younossi ZM, Jiang Y, Smith NJ, Stepanova M, Beckerman R, Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology. May 2015;61(5):1471-1478.
  4. Hatswell A, Bardou M, Gallagher M, Beckerman R, Modelling Alchemy: The Impact of Unorthodox Trial Design on Health Technology Appraisal Strategy. ISPOR Connections. 2014;20(4).
  5. Cuche M, Beckerman R, Chowdhury CA, van Weelden MA. Early dialogue with health technology assessment bodies: a European perspective. International journal of technology assessment in health care. Dec 2014;30(6):571-578.
  6. Beckerman R, Chowdhury CA, Park S. Guardians of opportunity: emerging health technology assessment in Brazil, South Korea and Taiwan. Journal of Pharmaceutical Health Services Research. 2013;4(3):125-129.

Presentations

  1. Smith NJ, Beckerman R, Predictors of Positive Decision Outcomes by the Cancer Drugs Fund. Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2015;18(7):A336.
  2. Smith N, Beckerman R, Cost-Effectiveness Reviews By HTA Agencies: A Comparison Of Factors Leading To Unfavourable Reviews For Oncology Agents. Oral Session HT4. Presented at the ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal, May 2014.2014.
  3. Chowdhury CA, Cuche M, Van Weelden M, Beckerman R, A Tale of Two Audiences: Optimising Yield from Early Advice Consultation with HTA and Regulatory Organisations. Workshop W24. Presented at the ISPOR 17th Annual Europe Meeting, Amsterdam, Netherlands, November 2014.2014.
  4. Chowdhury CA, Beckerman R, Bardou M. Alternative and Early Access Schemes: Short-Term Gains and Long-Term Sustainability. Presented at the ISPOR 17th Annual Europe Meeting, Amsterdam, Netherlands, November 2014.2014.
  5. Bustamante MMD, Beckerman R, Gallagher M, Bardou M. Lost and Found in Translation: How Does Evidence Predict Reimbursement and Pricing of High Value Specialty Products? Presented at the ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal, May 2014.2014.
  6. Beckerman R, Duttagupta S, Lin A, Chowdhury CA. Going Local: Strategy, Techniques, and Efficiency in Asia-PAC Adaptation of USA and EU-based Economic Models. Workshop W2. Presented at the ISPOR 6th Asia-Pacific Meeting, Beijing, China, September 2014.2014.
  7. Chowdhury CA, Sorenson C, Beckerman R, Bustamante MMD. One Size Does Not Fit All: How Traditional Pricing and Reimbursement Policies Affect Orphan Disease Therapy. Workshop W17. Presented at the ISPOR 18th Annual International Meeting, New Orleans, LA, May 2013.2013.
  8. Chowdhury CA, Beckerman R, Gallagher M, Bustamante MMD. Modelling Approaches When Limited By Single-Arm Studies: An Analysis of Recent Oncology Examples. Workshop W14. Presented at the ISPOR 16th Annual European Meeting, Dublin, Ireland, November 2013.2013.
  9. Bustamante MMD, Beckerman R, Sorenson C, Chowdhury CA. The Role of HTA in Determining Orphan and Specialty Drug Coverage in Latin America. Workshop W14. Presented at the ISPOR 4th Bi-Annual Latin America Meeting, Buenos Aires, Argentina, September 2013.2013.
  10. Chowdhury CA, Martin de Bustamante MA, Sorenson C, Beckerman R, Distant Cries: Customising Trial Design and Evidence Submission in an Emerging Markets Intensive World. Workshop W10. Presented at the ISPOR 17th Annual International Meeting, Washington, DC, May 2012.2012.
  11. Chowdhury CA, Martin de Bustamante MA, Sorenson C, Beckerman R, Optimising Oncology Reimbursement When Limited By Single-Arm Single-Agent Trial Design. Workshop W24.. Presented at the ISPOR 17th Annual International Meeting, Washington, DC, May 2012.2012.
  12. Beckerman R, Sorenson C, Martin de Bustamante MA, Chowdhury CA. Unplanned Evidence: Implications of Investigator-Initiated Trials. Workshop W5. Presented at the ISPOR 15th Annual Europe Meeting, Berlin, Germany, November 2012.2012.

Posters

  1. Younossi Z, Henry L, Stepanova M, Younossi Y, Hunt S, Beckerman, R, Non-Alcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes (DM): A Costly Combination. Poster Mo1169. Presented at the Digestive Disease Week 2016. San Diego, CA2016.
  2. Younossi Z, Gordon S, Ahmed A, Dieterich D, Saab S, Beckerman, R, Reduction in Clinical and Economic Burden by Treating All Medicaid Patients with Chronic Hepatitis C (CHC): A Decision-Analytic Model. Poster Mo1168. Presented at the Digestive Disease Week 2016. San Diego, CA2016.
  3. Wong SL, Fujii R, Beckerman, R, Cost Offsets Associated With Rebif Use In First-Line Rrms: An Analysis Based on The Cochrane Collaboration Review And Real-World Persistence Data. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2015;18(7):A751-752.
  4. Smith N, Cordina G, Cheynel J, Blissett D, Beckerman, R, Cost-Effectiveness of Co-Administered Branded Therapies in Oncology: Pricing Insights from an Early Economic Model. Poster PCN98. Presented at the ISPOR 20th Annual International Meeting. Philadelphia, PA.2015.
  5. Smith N, Cordina G, Cheynel J, Blissett D, Beckerman, R, Case Studies of Cost-Effectiveness for Co-Administered Branded Oncology Products: Predictions from an Early Economic Model. Poster PCN97. Presented at the ISPOR 20th Annual International Meeting. Philadelphia, PA.2015.
  6. Phillips A, Solon C, Smith N, Jiang Y, Locklear J, Beckerman, R, A Pragmatic Literature Review of Network Meta-Analyses of Disease-Modifying Drugs in the Treatment of Multiple Sclerosis. Poster P3.232. Presented at the American Academy of Neurology 67th Annual Meeting, Washington, DC, April 2014.2015.
  7. Perumpail R, Smith N, Wong R, Younossi Z, Beckerman, R, Ahmed A. Predictors of Retransplantation in Liver Transplant Recipients: An Updated Analysis from UNOS/OPTN Database. Poster 877. Presented at The Liver Meeting 2015. San Francisco, CA.2015.
  8. Jayasekera C, Smith N, Perumpail R, et al. All-oral direct acting antivirals can offer significant cost savings and cost effectiveness for treating hepatitis C in medically underserved areas in the United States: Impact of task-shifting on access. Poster 1534. Presented at The Liver Meeting 2015. San Francisco, CA.2015.
  9. Gambari J, Beckerman, R, The Ceesp Economic Evaluation: Can Clinical Efficacy and Cost-Effectiveness Co-Exist in France. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2015;18(7):A556.
  10. Beckerman, R, Locklear JC, Smith NJ, Phillips AL. Cost Offset Analysis of Interferon Beta Disease Modifying Therapies In Relapsing-Remitting Multiple Sclerosis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2015;18(7):A752.
  11. Beckerman, R, Locklear JC, Jiang Y, Solon C, Smith NJ, Phillips AL. Best Practices for Network Meta-Analysis Methodology: Comparative Effectiveness of Interferon-Beta Therapies In Relapsing-Remitting Multiple Sclerosis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2015;18(7):A696.
  12. Beckerman, R, Locklear J, Smith N, Phillips A. Cost-Offset Analysis of Interferon Beta Disease-Modifying Therapies in Relapsing-Remitting Multiple Sclerosis. Poster G12. Presented at the Academy of Managed Care Pharmacy Nexus 2015. Orlando, FL.2015.
  13. Balu S, Cerezo-Camacho O, Smith NJ, Beckerman, R, Cost-Effectiveness of Ceritinib Versus Current Therapies for Chemotherapy-Experienced Anaplastic Lymphoma Kinase Positive Non-Small Cell Lung Cancer Patients in Mexico. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2015;18(7):A821.
  14. Younossi Z, Jiang Y, Smith N, Stepanova M, Beckerman, R, Sofosbuvir-Containing Regimens for Chronic Hepatitis C Infection: Insights from a Work Productivity Economic Model. Poster 1755. Presented at the AASLD Liver Meeting 2014. Boston, MA, November 2014.2014.
  15. Xenakis A, Smith N, Beckerman, R, et al. A decision-analytic model of idelalisib and rituximab combination therapy versus rituximab monotherapy in relapsed, unfit chronic lymphocytic leukemia. Abstract 7101. Presented at the 2014 ASCO Annual Meeting, Chicago, IL, June 2014.2014.
  16. Xenakis A, Beckerman, R, Strategies To Overcome Hurdles In Hta Appraisals Amid Limitations Resulting From Single-Arm Trial Data. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2014;17(7):A729.
  17. Sun D, Solon C, Park S, Beckerman, R, An Analysis of the Drivers of Pricing Premiums Granted to Innovative Products in Japan. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2014;17(7):A795.
  18. Sun D, Park S, Jiang Y, Solon C, Beckerman, R, Correlation of Recent HTA Decisions Between Taiwan and Korea: Implication for Launch Strategies. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2014;17(7):A796.
  19. Sun D, Beckerman, R, Bustamante MMD. Correlation of HTA Decision Outcomes in France and Germany. Poster PCN192. Presented at the ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal, May 2014.2014.
  20. Sun D, Beckerman, R, Difference Between United States And Eu Authorisation Timelines And Time To Reimbursement In The Eu5. Poster PHP45. Presented at the ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal, May 2014.2014.
  21. Smith N, Xenakis A, Beckerman, R, Chhatwal J, Gregory S, Briggs A. A decision-analytic model of idelalisib in relapsed or refractory patients with indolent non-Hodgkin lymphoma. Abstract e17655. Presented at the 2014 ASCO Annual Meeting, Chicago, IL, June 2014.2014.
  22. Smith N, Xenakis A, Beckerman, R, Chhatwal J, Gregory S, Briggs A. A decision-analytic model of idelalisib in relapsed or refractory patients with follicular lymphoma in the United States. Abstract 30. Presented at the 2014 ASCO Quality Care Symposium, Boston, MA, October 20142014.
  23. Smith N, Beckerman, R, Best Practices and Key Challenges in Cost-Effectiveness Modelling of Multiple Sclerosis Therapies. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2014;17(7):A809.
  24. Park S, Jiang Y, Sun D, Beckerman, R, An Analysis of Pricing Premiums Granted Through Submitting Local RCT and Pharmacoeconomics Data in Taiwan. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2014;17(7):A793.
  25. Park S, Jiang Y, Sun D, Beckerman, R, An Analysis of the Key Value Drivers for HTA Assessments In Taiwan. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2014;17(7):A794.
  26. Nanguneri S, Ezcurra D, Cespedes A, Xenakis A, Beckerman, R, A Cost Minimisation Analysis Of Gonadotropins For In Vitro Fertilization Ovarian Stimulation On Oocyte- And Embryo-Based Endpoints. Poster PIH44. Presented at the ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal, May 2014.2014.
  27. Nanguneri S, Ezcurra D, Cespedes A, Xenakis A, Beckerman, R, A Cost Minimisation Analysis Of Gonadotropins For In Vitro Fertilization Ovarian Stimulation On Pregnancy- And Live Birth-Based Endpoints In Germany. Poster PIH42. Presented at the ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal, May 2014.2014.
  28. Monoson L, Martin de Bustamante MA, Beckerman, R, Time to Reimbursement for Oncology Agents from EMA Marketing Authorization to AIFA Approval AS “C(NN)” Class versus. AIFA Approval AS “A” or “H” Class. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2014;17(7):A740.
  29. Meletiche DM, Rutkowski T, Martin de Bustamante MA, Chowdhury CA, Beckerman, R, Modelling the Impact of Persistence Improvements with an Electronic Injection Device on Escalation to 2nd Line Treatment in Patients with Relapsing Remitting Multiple Sclerosis (RRMS). Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. Nov 2014;17(7):A390.
  30. Meletiche DM, Park S, Rutkowski T, Chowdhury CA, Beckerman, R, A Budget Impact Analysis of the Cochrane Collaboration Review of First-Line Treatments for Relapsing-Remitting Multiple Sclerosis. Poster G8EM. Presented at the Academy of Managed Care Pharmacy 26th Annual Meeting and Expo, April 20142014.
  31. Kim E, Joinnides M, Beckerman, R, Gould A, Wong K. Payer Management Of Oral Multiple Sclerosis Therapies In United States. Poster PND58. Presented at the ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal, May 2014.2014.
  32. Joinnides M, Beckerman, R, An Appraisal Of pCODR’s Decisions and Influence Over the Last 3 Years. Poster PCN182. Presented at the ISPOR 19th Annual International Meeting, Palais des Congrès de Montréal, May 2014.2014.

We work closely with you and tailor our approach based on your specific needs and those of your stakeholders.